Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + sorafenib
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Capecitabine + sorafenib is an oral combination therapy used in oncology. Capecitabine is a prodrug of 5-fluorouracil (5-FU), an antimetabolite that interferes with DNA synthesis and disrupts protein synthesis by inhibiting thymidylate synthase, leading to apoptosis in rapidly dividing tumor cells. Sorafenib is a multikinase inhibitor that targets several kinases involved in tumor cell proliferation and angiogenesis, including RAF kinase (C-Raf and B-Raf), vascular endothelial growth factor receptors (VEGFR-1/2/3), platelet-derived growth factor receptor beta (PDGFR-β), KIT, FMS-like tyrosine kinase 3 (FLT-3), and RET. The combination has been investigated for use in metastatic colorectal cancer and advanced hepatocellular carcinoma among other solid tumors[1][2][4][6].
- Brand names
- Nexavar
- Other names
- sorafenib and capecitabinesorafenib tosylate + capecitabine
02
Targets
TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)BRAF (B-Raf proto-oncogene, serine/threonine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on capecitabine + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + sorafenib.